CFDE Data Portal | Search CXCL2

	Label	Description
	CXCL2 Gene (Entity type)	ENSG00000081041 - C-X-C motif chemokine ligand 2
	CXCL2 associations Collection (Entity type)	Associations for CXCL2_associations
	GSE138789 metformin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE172016 2 V 0 PACLITAXEL HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE197555 0 V 3 TRAMETINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE200982 PLAC8 knockout 0 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE48812 sulforaphane 4 v 10 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE192750 adipose overexpression Grunt Fin PNMR OE 1 v 9 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE192860 0 V 1 TRIFLUOPERAZINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 2 v 13 human up Gene Set (Entity type)	A Gene Set from LINCS

CXCL2

ENSG00000081041 - C-X-C motif chemokine ligand 2

CXCL2 associations

Associations for CXCL2_associations

GSE138789 metformin 0 v 1 human up

A Gene Set from LINCS

GSE172016 2 V 0 PACLITAXEL HUMAN DN

A Gene Set from LINCS

GSE197555 0 V 3 TRAMETINIB HUMAN UP

A Gene Set from LINCS

GSE200982 PLAC8 knockout 0 v 2 human dn

A Gene Set from LINCS

GSE48812 sulforaphane 4 v 10 human dn

A Gene Set from LINCS

GSE192750 adipose overexpression Grunt Fin PNMR OE 1 v 9 human up

A Gene Set from LINCS

GSE192860 0 V 1 TRIFLUOPERAZINE HUMAN UP

A Gene Set from LINCS

GSE111247 temozolomide LN-308 2 v 13 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.